Sofinnova Partners
Finance · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7-11 Boulevard Haussmann, Paris, Ile-de-...Website
www.sofinnovapartners.comRevenue
$41.2 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
1
2
2
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the company's collective future.Explore more
Sofinnova Partners Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sofinnova Partners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Sofinnova Partners had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sofinnova Partners has new funding data
Check out if Sofinnova Partners is spiking on competitors!
Check if Sofinnova Partners has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Sofinnova Partners, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Sofinnova Partners
Earning: See what the market has to say on Sofinnova Partners recently announced quarterly report
Product Launch: Get notified when Sofinnova Partners launches new products
Recommended Actions
Reach out to Masked Content who joined Sofinnova Partners as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Sofinnova Partners is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Sofinnova Partners is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Sofinnova Partners.
Sofinnova Partners financials insights
Gather financial insights about Sofinnova Partners, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$1B
Sofinnova Partners Tech Stack
A closer look at the technologies used by Sofinnova Partners
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Executive Move
Executive Moves, Board of Directors
Project
Spending/Investment
Sofinnova Partners News & Media
P2 Science Closes $23 Million Round to Accelerate Commercial Momentum and Expand Green Chemistry Platform into New Markets
Sofinnova Partners leads oversubscribed round joined by new and returning strategic investors, fueling expansion of P2's award-winning beauty and personal care portfolio and entry into performance polymers, home care, coatings, and crop care WOODBRIDGE, Conn., May 26, 2026 /PRNewswire/ --...UK: CellCentric raises US$220m in oversubscribed Series D financing
CellCentric raises US$220m in oversubscribed Series D financingNeurent Medical Raises €62.5 Million in Series C Financing
Neurent Medical raises €62.5 million in a Series C funding round for its product development and commercial expansion.Signadori Bio appoints Dr. Selwyn Ho, MB BS as Chief Executive Officer to lead company ...
Dr. Selwyn Ho takes over from Matthieu Coutet, Partner at Sofinnova Partners, who will move into the role of Chair of the Board at Signadori Bio Transition follows promising pre-clinical proof of concept data demonstrating potent cancer cell killing across multiple cancer types using Signadori Bio’s core immunotherapy technology, engineering monocytes to express P21 (CDKN1A), a master regulator of myeloid anti-tumour activity (ANSA)
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sofinnova Partners
Sign Up For FreeTo access detailed company insights
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the... Read More
